Opendata, web and dolomites

QuickMIC

QuickMIC™ - an ultra-rapid diagnostic system for Antibiotic Susceptibility Testing (AST)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 QuickMIC project word cloud

Explore the words cloud of the QuickMIC project. It provides you a very rough idea of what is the project "QuickMIC" about.

infection    tested    resistance    price    clinical    bacterial    people    image    diagnosis    approx    patented    rates    antibiotics    appropriate    worldwide    patient    antimicrobial    quickmic    besides    commercializing    innovation    ast    ed    susceptibility    business    decrease    competitors    ivd    escalating    direct    2019    usually    time    commercialisation    contribution    significantly    ultra    competitiveness    fastest    death    fighting    microfluidics    successful    empirically    guide    golden    effort    platform    rapid    survival    unmet    treating    antibiotic    samples    alternative    reduce    additionally    spectrum    diagnostic    globally    plan    48    tool    amr    standard    treat    contributes    combining    blood    hours    gradientech    patients    million    survive    market    marking    treatment    improvement    quicker    detection    sepsis    disease    ce    misuse    doctors    empirical    more    unsuccessful    continued    continuous    trade   

Project "QuickMIC" data sheet

The following table provides information about the project.

Coordinator
GRADIENTECH AB 

Organization address
address: UPPSALA SCIENCE PARK
city: UPPSALA
postcode: 75183
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://gradientech.se/funding-horizon-2020-sme-instrument/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GRADIENTECH AB SE (UPPSALA) coordinator 50˙000.00

Map

 Project objective

The aim of the project is to bring QuickMIC™, an ultra-rapid diagnostic tool for Antibiotic Susceptibility Testing (AST) to the market and clinical practice. AST is usually carried out to determine which antibiotic will be the most appropriate in treating a bacterial infection in a particular patient. Sepsis is the major cause of death as a result of an infection today. It affects approx. 30 million of people every year worldwide. About 20 % of the patients do not survive the disease. Currently, it can take up to 48 hours for the current golden standard AST method to produce reliable diagnostic results. Therefore, doctors empirically treat sepsis patients with wide-spectrum antibiotics while the blood samples are being tested. The globally escalating antimicrobial resistance (AMR) has resulted in empirical treatment being unsuccessful more and more often. Misuse of antibiotics additionally contributes to increasing resistance. The improvement of survival rates in sepsis and the decrease in AMR will only be possible with access to a quicker AST tool. To address this unmet clinical need, Gradientech is developing an ultra-rapid AST system, QuickMIC™, based on a patented technology platform. By combining i) advanced microfluidics and ii) continuous image detection and analysis, QuickMIC™ can reduce the time of an AST to two hours. Besides being the fastest AST under development, QuickMIC™ is also a low-price alternative compared to its direct competitors. By commercializing QuickMIC™, Gradientech will make an important contribution to fighting AMR in Europe. Moreover, we will significantly improve the diagnosis and treatment of sepsis. A continued development of QuickMIC™ will result in a CE-IVD marking by early 2019. In the Phase 1 project, we will develop a business plan that will guide the future clinical studies and commercialisation activities. If successful, the overall innovation effort will take Gradientech to a new level of competitiveness and growth.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "QUICKMIC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "QUICKMIC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

STURSKIN (2018)

Innovative products by using tanned sturgeon skin

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More